ADXN

Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

Wall Street analysts forecast ADXN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADXN is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Addex Therapeutics Ltd revenue for the last quarter amounts to 62.01K USD, decreased -7.97 % YoY.

Addex Therapeutics Ltd. EPS for the last quarter amounts to -0.02 USD, decreased -0.00 % YoY.

Addex Therapeutics Ltd (ADXN) has 2 emplpoyees as of December 15 2025.

Today ADXN has the market capitalization of 9.98M USD.